Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

(2020) Zunyou Wu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

(2020) Xiaobo Yang et al.   Lancet Respiratory Medicine

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy

(2020) Paola Toniati et al.   AUTOIMMUNITY REVIEWS

Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia

(2020) Ruggero Capra et al.   European Journal of Internal Medicine

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

(2020) Safiya Richardson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy

(2020) Giacomo Grasselli et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis

(2020) Zhaohai Zheng et al.   JOURNAL OF INFECTION

Tocilizumab treatment in COVID-19: A single center experience

(2020) Pan Luo et al.   JOURNAL OF MEDICAL VIROLOGY

Why tocilizumab could be an effective treatment for severe COVID-19?

(2020) Binqing Fu et al.   Journal of Translational Medicine

Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients

(2020) T. Klopfenstein et al.   MEDECINE ET MALADIES INFECTIEUSES

Effective treatment of severe COVID-19 patients with tocilizumab

(2020) Xiaoling Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)

(2020) Marta Colaneri et al.   Microorganisms

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

(2020) Bingwen Liu et al.   JOURNAL OF AUTOIMMUNITY

Prediction of infection risk in rheumatoid arthritis patients treated with biologics

(2019) Meghna Jani et al.   CURRENT OPINION IN RHEUMATOLOGY

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

(2017) Rudragouda Channappanavar et al.   Seminars in Immunopathology

Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis

(2012) Fabrizio De Benedetti et al.   NEW ENGLAND JOURNAL OF MEDICINE